^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CBP inhibitor

    Related drugs:
    5d
    Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results. (PubMed, JTO Clin Res Rep)
    FZEC demonstrated modest antitumor activity, and observed AEs were generally manageable in patients with heavily pretreated NSCLC. NCT03386942.
    P1 data • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202)
    5d
    A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) (clinicaltrials.gov)
    P1, N=50, Recruiting, Aurigene Discovery Technologies Limited | Trial primary completion date: Jun 2025 --> Jan 2027
    Trial primary completion date • First-in-human
    |
    AUR-107
    9d
    TT-CSP-001: A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, TOLREMO therapeutics AG | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    9d
    Role of the cross-regulation between Wnt pathway activation and androgen receptor signaling in prostate cancer treatment resistance. (PubMed, Cell Death Differ)
    Targeting β-catenin interactions with co-activators p300/CBP using selective inhibitors (IQ-1 and ICG-001) effectively mitigated Wnt-driven ARSI resistance, restoring sensitivity to therapy in preclinical models...The identified Wnt signature holds potential as a biomarker for predicting and monitoring therapeutic outcomes. Concurrent targeting of AR and Wnt signaling represents a promising strategy to overcome treatment resistance, particularly in patients with Wnt-activating mutations.
    Journal
    |
    RNF43 (Ring Finger Protein 43) • ZNRF3 (Zinc And Ring Finger 3)
    |
    foscenvivint (PRI724)
    13d
    MBC-EA: A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates (clinicaltrials.gov)
    P2, N=52, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • Halaven (eribulin mesylate)
    24d
    TT-CSP-001: A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid Tumors (2022-500849-24-00)
    P1, N=40, Active, not recruiting, Tolremo Therapeutics AG | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    26d
    JAZMINE: Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, MedSIR
    New P1/2 trial
    |
    HER-2 positive • HER-2 amplification
    |
    capecitabine • Halaven (eribulin mesylate) • Tukysa (tucatinib) • Ziihera (zanidatamab-hrii)
    26d
    CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors. (PubMed, Clin Cancer Res)
    These clinical and preclinical findings provide rationale for therapies to increase therapeutic index of aPD-1 therapy by diminishing presence of T cell-suppressive myelomonocytic cells to improve outcomes for patients with refractory disease.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Halaven (eribulin mesylate) • Turalio (pexidartinib)
    1m
    Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Fudan University
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate)
    1m
    SWOG S1937: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (clinicaltrials.gov)
    P3, N=184, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • paclitaxel • docetaxel • Halaven (eribulin mesylate) • Trodelvy (sacituzumab govitecan-hziy)
    1m
    SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    HER-2 positive • HR positive • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative
    |
    Halaven (eribulin mesylate) • izorlisib (MEN1611)
    2ms
    Study of E7386 in Participants With Selected Advanced Neoplasms (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Eisai Inc. | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    E7386